Stakeholder Buy-In for Adaptive Rare Disease Studies
Stakeholder Buy-In for Adaptive Rare Disease Studies Building Stakeholder Consensus for Adaptive Designs in Rare Disease Trials Introduction: The Human Element in Adaptive Trial Success Adaptive trial designs are transforming how we approach rare disease clinical research. These designs allow for protocol modifications based on interim data—enhancing efficiency, flexibility, and ethical oversight. However, their successful…
Read More “Stakeholder Buy-In for Adaptive Rare Disease Studies” »